WebJun 24, 2024 · As the space continues to reel from Biogen’s major Phase III flop last week, Roche is handing back rights to a program from 4D Molecular Therapeutics, the biotech … WebApr 27, 2015 · SAN FRANCISCO-- ( BUSINESS WIRE )--4D Molecular Therapeutics (4DMT), a leader in next-generation gene therapy vector discovery and product development, today …
4DMT and ROCHE Expand Ophthalmology Partnership to Develop …
WebSep 19, 2024 · EMERYVILLE, Calif.-- ( BUSINESS WIRE )--4D Molecular Therapeutics (4DMT), a leader in adeno-associated virus (AAV) gene therapy vector discovery and product development, today announced $3 million in additional funding from Cystic Fibrosis Foundation Therapeutics Inc., (CFFT) the non-profit drug discovery and development … WebJun 16, 2024 · In 2024, 4DMT expects to initiate clinical trials for 4D-310, its wholly-owned product candidate for the treatment of Fabry disease, and two ophthalmology product candidates: 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), a wholly-owned candidate subject to an exclusive option for Roche to develop and commercialize, and 4D ... midwest motor sports hartford illinois
Press Release - 4D Molecular Therapeutics
Web4D Molecular Therapeutics (4DMT), a leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development, today … WebMay 1, 2024 · Roche and 4DMT’s first collaboration program is for 4D-110, a clinical candidate to treat choroideremia (an inherited form of night blindness that can show up in … WebJul 27, 2024 · 4DMT is a clinical-stage precision gene medicines company harnessing the power of directed evolution to unlock the full potential of gene therapy for rare and large market diseases in lysosomal storage diseases, ophthalmology, neuromuscular diseases, and cystic fibrosis. 4DMT’s proprietary Therapeutic Vector Evolution platform enables a … newton heating and plumbing